Meng Yuan, Yiquan Wang, Huibin Lv, Timothy J C Tan, Ian A Wilson, Nicholas C Wu
Cell reports 2022 Oct 27As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concerns (VOCs) continue to emerge, cross-neutralizing antibody responses become key toward next-generation design of a more universal COVID-19 vaccine. By analyzing published data from the literature, we report here that the combination of germline genes IGHV2-5/IGLV2-14 represents a public antibody response to the receptor-binding domain (RBD) that potently cross-neutralizes a broad range of VOCs, including Omicron and its sub-lineages. Detailed molecular analysis shows that the complementarity-determining region H3 sequences of IGHV2-5/IGLV2-14-encoded RBD antibodies have a preferred length of 11 amino acids and a conserved HxIxxI motif. In addition, these antibodies have a strong allelic preference due to an allelic polymorphism at amino acid residue 54 of IGHV2-5, which is located at the paratope. These findings have important implications for understanding cross-neutralizing antibody responses to SARS-CoV-2 and its heterogenicity at the population level as well as the development of a universal COVID-19 vaccine. Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Meng Yuan, Yiquan Wang, Huibin Lv, Timothy J C Tan, Ian A Wilson, Nicholas C Wu. Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2. Cell reports. 2022 Oct 27;41(7):111650
PMID: 36335937
View Full Text